Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
Open Access
- 30 May 2024
- journal article
- research article
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (05) , 694-700
Abstract
Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020. Since then, there has been an urgent need for effective therapeutic methods to manage the disease. We aimed to assess the effectiveness of molnupiravir in reducing the need for hospitalization in at-risk, non-hospitalized COVID-19 patients. Methodology: This was a single-center, non-randomized, observational retrospective study of non-hospitalized patients with confirmed COVID-19, treated at the Clinic for Infectious and Tropical Diseases, University Clinical Center in Belgrade, Serbia. Results: The study was conducted between 15 December 2021 and 15 February 2022 and included 320 patients. Of these, 165 (51.6%) received treatment with molnupiravir. The study and control groups were similar in gender and age distribution. The study group had a higher proportion of vaccination (75.2% vs. 51%, p < 0.001). There was no statistically significant difference in presence of comorbidity within the groups. Majority of the patients who received molnupiravir did not require hospitalization; and this was statistically significant in comparison to control group (92.7 vs. 24.5%, p < 0.001). Oxygen supplementation was less frequently required in the study group compared to the control group (0.6% vs. 31%, p < 0.001). During the follow-up period of 12.12 ± 3.5 days, significantly less patients from the study group were admitted to the intensive care unit (p < 0.001). Molnupiravir significantly reduced the risk of hospitalization by 97.9% (HR 0.021; 95% CI 0.005-0.089; p < 0.001). Conclusions: Molnupiravir is an effective therapy in preventing the development of severe forms of COVID-19 and hospitalization.Keywords
This publication has 20 references indexed in Scilit:
- Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serologyNature Communications, 2023
- Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort studyJournal of Infection, 2023
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialThe Lancet, 2022
- Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19The Lancet Regional Health - Western Pacific, 2022
- Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominancePharmacological Reports, 2022
- Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19NEJM Evidence, 2022
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2021
- Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19Current Opinion in Virology, 2021
- Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA templateJournal of Biological Chemistry, 2021
- Risk Factors for Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization: COVID-19–Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance SystemClinical Infectious Diseases, 2020